Published in Obesity and Diabetes Week, December 20th, 2004
The agreement includes exclusive commercial rights to issued U.S. patent 5,604,203, which relates to analogs of Peptide YY, or peptide derivatives, and uses thereof as therapeutic agents in the treatment of gastroenterological disorders; issued U.S. patents 6,013,633, 6,235,718 and 6,737,408, which relates to compounds for control...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Obesity and Diabetes Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.